James L. Herman's most recent trade in Cumberland Pharmaceuticals Inc. was a trade of 2,500 Options (right to buy) done . Disclosure was reported to the exchange on March 18, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cumberland Pharma Inc | James L. Herman | VP and Chief Compliance Office | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2026 | 2,500 | 21,000 | - | - | Options (right to buy) | |
| Cumberland Pharma Inc | James L. Herman | VP and Chief Compliance Office | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2025 | 2,500 | 18,500 | - | - | Options (right to buy) | |
| Cumberland Pharma Inc | James L. Herman | VP and Chief Compliance Office | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2024 | 4,000 | 16,000 | - | - | Options (right to buy) | |
| Cumberland Pharma Inc | James L. Herman | VP and Chief Compliance Office | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.81 per share. | 23 Mar 2024 | 1,186 | 38,255 (0%) | 0% | 1.8 | 2,147 | Common Stock |
| Cumberland Pharma Inc | James L. Herman | VP and Chief Compliance Office | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 4,000 | 12,000 | - | - | Options (right to buy) | |
| Cumberland Pharma Inc | James L. Herman | VP and Chief Compliance Office | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.92 per share. | 18 Mar 2023 | 1,280 | 39,441 (0%) | 0% | 1.9 | 2,458 | Common Stock |
| Cumberland Pharma Inc | James L. Herman | VP and Chief Compliance Office | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2022 | 6,000 | 6,000 | - | - | Options (right to buy) | |
| Cumberland Pharma Inc | James L. Herman | VP and Chief Compliance Office | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.74 per share. | 16 Mar 2022 | 1,280 | 40,721 (0%) | 0% | 2.7 | 3,507 | Common Stock |